New CGM system aims to improve blood sugar control in diabetes patients
NCT ID NCT06904846
First seen Jan 15, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This study is testing a new continuous glucose monitor (CGM) called iCan O3 in 70 adults with type 1 or type 2 diabetes. Participants will wear the device for 60 days to see if it helps them keep their blood sugar in a healthy range more often. The goal is to improve diabetes control and reduce the need for fingerstick tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UZA ANTWERP UZA Dienst Endocrinologie
Antwerp, Belgium
Conditions
Explore the condition pages connected to this study.